It is made available under a CC-BY 4.0 International license .

# Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance and high Spike-specific neutralizing antibodies

3

Authors: Elena Montes-Cobos<sup>1</sup>, Victoria C Bastos<sup>1,4</sup>, Clarice Monteiro<sup>1</sup>, João CR de Freitas<sup>1</sup>, 4 Heiny DP Fernandes<sup>1</sup>, Clarice S Constancio<sup>2</sup>, Danielle AS Rodrigues<sup>3</sup>, Andreza MDS Gama<sup>1</sup>, 5 Vinicius M Vidal<sup>1</sup>, Leticia S Alves<sup>1</sup>, Laura Zalcberg-Renault<sup>1,4</sup>, Guilherme S de Lira<sup>1,4</sup>, Victor 6 A Ota<sup>1,4</sup>, Carolina Caloba<sup>6</sup>, Luciana Conde<sup>3</sup>, Isabela C Leitão<sup>4</sup>, Amilcar Tanuri<sup>5</sup>, Orlando DC 7 Ferreira<sup>5</sup>, Renata M Pereira<sup>6</sup>, André M Vale<sup>3</sup>, Terezinha M Castiñeiras<sup>4</sup>, Dominique Kaiserlian 8 <sup>7,†</sup>, Juliana Echevarria-Lima <sup>2,†</sup>, Marcelo T Bozza <sup>1,†,\*</sup>. 9 10 Affiliations: 11 <sup>1</sup> Laboratório de Inflamação e Imunidade, Instituto de Microbiologia Paulo de Góes, Universidade 12 Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 13 <sup>2</sup> Laboratório de Imunologia Básica e Aplicada, Instituto de Microbiologia Paulo de Góes, 14 Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 15 <sup>3</sup> Laboratório de Biologia de Linfócitos, Instituto de Biofísica Carlos Chagas Filho, Universidade 16 Federal do Rio de Janeiro, Rio de Janeiro, Brazil 17 <sup>4</sup> Departamento de Doenças Infecciosas e Parasitárias, Faculdade de Medicina, Universidade 18

- 19 Federal do Rio de Janeiro, Rio de Janeiro, Brazil
- 20 <sup>5</sup> Laboratório de Virologia Molecular, Instituto de Biologia, Universidade Federal do Rio de
- 21 Janeiro, Rio de Janeiro, Brazil
- <sup>6</sup> Laboratório de Imunologia Molecular, Instituto de Microbiologia Paulo de Góes, Universidade
- 23 Federal do Rio de Janeiro, Rio de Janeiro, Brazil

It is made available under a CC-BY 4.0 International license .

- <sup>7</sup> Mucosal Immunity Vaccination & Biotherapies Laboratory, INSERM U1060, Université Claude
- 25 Bernard Lyon 1, Centre hospitalier Lyon-Sud, Pierre-Benite, France
- 26

27 \*Corresponding authors: <u>mbozza@micro.ufrj.br.</u>

<sup>28</sup> <sup>†</sup>Contributed equally to the conceptualization of the work

29

Summary: The vast spectrum of clinical features of COVID-19 keeps challenging scientists and 30 clinicians. Control of pathogen load (host resistance) and prevention of tissue damage (disease 31 tolerance) are essential for the outcome of infectious diseases. Both low resistance and high disease 32 33 tolerance might result in long-term viral persistence, but the underlying mechanisms remain unclear. Here, we studied the immune response of immunocompetent COVID-19 patients with 34 prolonged SARS-CoV-2 infection by immunophenotyping, cytokine and serological analysis. 35 Despite viral loads and symptoms comparable to regular mildly-symptomatic patients, long-term 36 carriers displayed weaker systemic IFN-I responses and fewer circulating pDCs and NK cells at 37 disease onset. Type 1 cytokines remained low, while type-3 cytokines were in turn enhanced. 38 Interestingly, the plasma of these patients showed a higher spike-specific neutralization capacity. 39 40 The identification of very early distinct immune responses in long-term carriers adds up to our 41 understanding on essential host protective mechanisms to ensure tissue damage control despite prolonged viral infection. 42

43

Key words: SARS-CoV-2, host resistance, disease tolerance, persistent infection, IFN-I, Type 1/3
immunity, neutralizing antibodies.

46

It is made available under a CC-BY 4.0 International license .

#### 47 **INTRODUCTION**

Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 48 have clinical presentations ranging from asymptomatic-mildly symptomatic (70-90%) to severe 49 and critical (10-30%)  $^{1-4}$ . These different clinical outcomes, including the risk of COVID-19-50 related death, have been associated with age, gender, and underlying comorbidities, such as obesity 51 and diabetes <sup>2,5,6</sup>. Hospitalized patients with severe COVID-19 present an increase in inflammatory 52 53 cytokines, monocytes and neutrophils, and a marked decrease in lymphocytes compared to patients with mild disease <sup>7-9</sup>. Moreover, a significant fraction of patients with life-threatening COVID-19 54 present defects in type I IFNs (IFN-I) due to inborn mutations and auto-antibodies, pointing to a 55 critical role of IFN-I in the immune response against SARS-CoV-2<sup>10-12</sup>. These distinct immune 56 and inflammatory signatures are observed early after COVID-19 diagnosis, correlate with 57 divergent disease trajectories and might have prognostic value <sup>9,13,14</sup>. 58

The interplay of resistance to limit pathogen burden and maintenance of tissue homeostasis, 59 also known as disease tolerance, is central to host and pathogen interactions and determines disease 60 progression and outcome <sup>15,16</sup>. Whilst resistance represents the ability to contain pathogen 61 replication and spread in the host, disease tolerance reflects the capacity to limit deleterious effects 62 of infectious agents and the associated inflammatory response. Indeed, critically ill COVID-19 63 64 patients present local and systemic inflammation with severe tissue dysfunction regardless of pathogen loads <sup>9,13,14</sup>. Alternatively, immunosuppressed individuals, who exemplify the paradigm 65 of low host resistance, display a variety of clinical presentations, from asymptomatic to severe <sup>17–</sup> 66 67 <sup>20</sup>. These observations suggest that disease tolerance mechanisms controlling tissue homeostasis might underly a benign clinical course of SARS-CoV-2 infection and determine the fitness of 68 COVID-19 patients<sup>21</sup>. 69

It is made available under a CC-BY 4.0 International license .

Low resistance might impact SARS-CoV-2 clearance in multiple ways, leading to high viral titers 70 in the upper-respiratory tract (URT), dissemination to other tissues, especially the lungs, or long-71 term virus persistence. Although viral persistence has been more frequently described in 72 immunosuppressed patients, persistent URT infection and long-term virus shedding have been 73 documented in immunocompetent patients with asymptomatic or mild COVID-19 as well <sup>22-26</sup>. 74 75 Most long-term carriers remained SARS-CoV-2 positive by qRT-PCR despite seroconversion, reinforcing the risk of continuous SARS-CoV-2 transmission <sup>23,27,28</sup>. Defects in antigen-specific 76 cytotoxic T cell responses were found in such patients <sup>29</sup>, but the immune dynamics during the first 77 78 days of infection remains unclear. Thus, the aim of this study is to gain insights into the immune mechanisms associated to prolonged SARS-CoV-2 infection in oligosymptomatic, 79 immunocompetent subjects. First, we identified early pathophysiological immune markers that 80 may predict COVID-19 progression. Overall, our study reveals alternative immune strategies to 81 cope with SARS-CoV-2 infection, shedding light on the mechanisms of resistance and disease 82 tolerance in COVID-19. 83

84

85

#### 86 **RESULTS**

### 87 Demographic characterization of study cohort

Our study cohort is composed of individuals tested for SARS-CoV-2 infection at the Diagnostic Screening Center for COVID-19 of the Federal University of Rio de Janeiro (CTD-UFRJ) from April to December 2020. Weekly follow-up was offered to those subjects who tested positive for the presence of SARS-CoV-2 RNA by quantitative PCR with reverse transcription (RT-qPCR) in nasopharyngeal swab samples, until SARS-CoV-2 RNA was no longer detectable.

It is made available under a CC-BY 4.0 International license .

Initial studies performed in the CTD-UFRJ cohort found a median of SARS-CoV-2 RT-qPCR 93 positivity around three weeks after symptoms onset <sup>22</sup>. Day 21 after symptom onset (DSSO) was 94 thus used as a putative threshold time point of viral clearance from the URT. From those 95 individuals who volunteered to longitudinal follow-up testing, we selected 33 patients with 96 persistent SARS-CoV-2 infection (P), representing long-term carriers, defined by detectable 97 98 SARS-CoV-2 RNA (i.e. Ct < 38) at  $\geq 21$  DSSO. Thirty-two SARS-CoV-2 infected patients with a negative RT-qPCR (i.e.  $Ct \ge 38$ ) at  $\le 21$  DSSO were also included as COVID-19 control study 99 group, thereafter referred to as non-persistent (NP), and 24 age- and gender-matched 100 101 asymptomatic, non-infected individuals (confirmed by the absence of spike-specific IgM and IgG in the plasma) were selected as the reference group (NI) (Fig. 1A). The proportion of men and 102 women was equally distributed among the study groups. The median age distribution was 36 103  $(\pm 9.67)$  years of age for the NI group, 36  $(\pm 11.05)$  for the those of the NP group and 38  $(\pm 12.13)$ 104 for patients with persistent SARS-CoV-2 infection (P). COVID-19 patients included in this study 105 were either oligosymptomatic, presenting mild symptoms including fever, headache, cough, 106 sneeze, anosmia or myalgia, or asymptomatic at the time of enrollment. Despite prolonged URT 107 infection, long term carriers displayed neither a significantly longer duration of symptoms (Fig. 108 109 1B) nor augmented disease severity markers in the plasma (Fig. 1C). None of the patients of our cohort developed severe COVID-19 requiring hospitalization or oxygen therapy. The most 110 common comorbidities reported by the patients were hypertension (15.63% of NP versus 27.28% 111 112 of P), hypothyroidism (6.25% NP versus 12.12% of P), and diabetes mellitus (6.25% of NP versus 3.03% of P) (Table 1). 113

It is made available under a CC-BY 4.0 International license .

#### 115 **Table 1. Demographics of patient cohort**

- 116
- 117

	Non persistent ( <i>n</i> =32)	Persistent (n=33)	P value
Characteristics			
Age, median (years)	36 (±11.05)	38 (±12.13)	0.4606
Sex, female	16/32 (50%)	17/33 (51.52%)	
Last positive, median (DSSO)	5 (±3.2)	31 (±21.5)	< 0.0001
Comorbidities			
Hypertension	5/32 (15.63%)	9/33 (27.28%)	
Diabetes Mellitus	2/32 (6.25%)	1/33 (3.03%)	
Hypothyroidism	2/32 (6.25%)	4/33 (12.12%)	
Others	4/32 (12.50%)	5/33 (15.16%)	

- 118
- 119

#### 120 SARS-CoV-2 persistency does not depend on viral load or mucosal cytokines

121 As SARS-CoV-2 enters the organism via the URT, early local immunity at the 122 nasopharyngeal mucosa may be important for fast and efficient viral clearance. Therefore, we first 123 analyzed early viral loads and immune parameters in the nasopharyngeal mucosa of patients that 124 eventually developed prolonged SARS-CoV-2 infection. Viral titers, determined by qRT-PCR, in 125 nasopharyngeal swabs of long-term carriers were similar to those of non-persistent COVID-19 126 patients during the first days of infection ( $\leq 7$  DSSO). Long-term carriers presented detectable viral RNA in the URT for up to 4 weeks, albeit with slightly higher Ct values (Fig. 1D). Strikingly, 127 128 a group of patients still tested positive by RT-qPCR for longer than 8 weeks, with the latest 129 positivity result being at 134 DSSO in one patient (Fig. 1E).

130 Next, we used a multiplex assay to compare a set of 47 immune mediators, including IFNα, 131 IL29, IFNγ, IL-1β, IL-4, IL-13, IL-17A and IL-10, in nasopharyngeal swab samples collected at  $\leq$ 132 10 DSSO from a group of non-persistent patients (NP, *n*=9) and long-term carriers (P, *n*=13). The 133 results did not show any differences in early cytokines between both groups (Fig. 1F, Suppl. Fig.

It is made available under a CC-BY 4.0 International license .

- 134 1A). These results suggest that early alterations of these mucosal cytokines at the entry site of
- 135 SARS-CoV-2 do not drive viral persistence.

It is made available under a CC-BY 4.0 International license .

#### 137 **Fig 1.**



Figure 1. Overview of clinical features, viral loads, and mucosal immunity parameters of
 COVID-19 patients. (A) SARS-CoV-2 positivity by qRT-PCR in nasopharyngeal samples, sex

It is made available under a CC-BY 4.0 International license .

and age of non-infected controls (NI), non-persistent (NP) and persistent (P) COVID-19 patients. 142 (B) Duration of symptoms of NP and P patients, represented as days after symptom onset (DSSO). 143 (C) Quantification of the plasma damage markers D-dimer and Ferritin in NI (n=14), NP (n=26), 144 and P (n=24) at <10 DSSO by multiplex magnetics bead-based immunoassay. (D) Cycle threshold 145 (Ct) values of qRT-PCR for SARS-CoV-2 target genes from nasopharyngeal samples from NP 146 147 (n=32) and P (n=33) patients by DSSO. (E) SARS-CoV-2 positivity of NP (n=32) and P (n=33)patients by DSSO. (F) Quantification of IFNa, IL-29, IFNy, IL-1b, IL-4, IL-13, IL-17, and IL-10 148 from URT samples in NP (n=9) and P (n=13) at <10 DSSO by multiplex immunoassay. Each dot 149 150 represents a subject. Filled dots represent a positive qRT-PCR of nasopharyngeal samples for SARS-CoV-2, while empty dots represent a negative qRT-PCR. DSSO, Days since symptom 151 152 onset.

153

154

#### 155 Long-term carriers present reduced systemic type I IFN responses

Early dysregulated systemic inflammatory and antiviral responses have been pointed out 156 as potential drivers of distinct clinical progression of COVID-19<sup>9,10,13</sup>. To gain insights into 157 158 specific immune mechanisms leading to prolonged SARS-CoV-2 infection, we analyzed innate immune cells and soluble mediators in non-infected individuals, non-persistent COVID-19 159 160 patients, and long-term carriers early after disease onset ( $\leq 10$  DSSO). Long-term carriers 161 displayed a different distribution pattern of circulating monocyte populations, characterized by a drop in the frequency of classical (lin<sup>-</sup>CD14<sup>+</sup>CD16<sup>-</sup>) monocytes and a modest increase in the 162 percentage of non-classical (lin<sup>-</sup>CD14<sup>-</sup>CD16<sup>+</sup>) monocytes (Fig. 2A). Additionally, we found a 163 164 significant reduction of pDC frequencies (lin<sup>-</sup>CD14<sup>-</sup>CD304<sup>+</sup>) in the blood of these patients (Fig.

It is made available under a CC-BY 4.0 International license .

165 2B), which may be due to lower numbers of circulating pDCs or to higher tissue recruitment.

166 Nonetheless, we detected augmented expression of HLA-DR on this cell population, indicative of

- 167 a more mature phenotype and a predisposition to apoptosis  $^{30}$ . Other monocyte and dendritic cell
- 168 populations did not vary between both groups of patients (Suppl. Fig. 3A).

Since pDCs are the first and major IFN-I producers during viral infections <sup>31,32</sup>, it was not 169 unexpected that plasma concentrations of IFNa and IP-10 (CXCL10) in long-term carriers did not 170 increase as much as in non-persistent patients (Fig. 2C). Expression analysis of the interferon-171 inducible genes (ISGs) IRF7 and ISG-15 in PBMCs also showed reduced induction of both genes 172 in patients from the P group compared to those of the NP group (Fig. 2D). No differences were 173 observed in the plasma concentrations of IFN $\lambda$  (IL-29) (Fig. 2C), IFN $\beta$  or IFN $\omega$  (Suppl. Fig. 3B), 174 nor in the occurrence of anti-IFN $\alpha$ 2 autoantibodies (Fig. 2 E). Neither did we find changes in most 175 of the inflammatory mediators predictive of poor outcome in COVID-19, such as TNF $\alpha$ , MCP-1 176 (CCL2), IL1β, IL-6 or IL-1 RA (Fig. 2F, Suppl. Fig. 3B) <sup>7–9</sup>. Only plasma concentrations of the 177 regulatory cytokine IL-10 were lower in long-term carriers than in non-persistent patients. 178

Furthermore, we titrated plasma levels of molecules involved in tissue damage and repair 179 at disease onset, some of which have been previously connected to disease tolerance <sup>33</sup>. In contrast 180 181 to non-persistent patients, long-term carriers showed no increase in tissue growth factors like PDGF-BB, basic FGF and VEGF, indicating that systemic tissue repair mechanisms were not 182 183 induced in these patients (Fig. 2F). Syndecan-1, involved in modulation of inflammation and tissue repair and a hallmark of endothelial damage <sup>34</sup>, was comparable in all groups. Collectively, our 184 results show altered innate immune responses, a weaker antiviral state and limited induction of 185 186 tissue repair during the first days of prolonged SARS-CoV-2 infection.

It is made available under a CC-BY 4.0 International license .

188 Fig. 2



189

It is made available under a CC-BY 4.0 International license .

## 191 Figure 2. Early innate immune profiles distinguish between persistent and non-persistent patients. Immunophenotyping of innate immune cell populations in PBMC from NI (n=15), NP 192 (n=22) and P (n=27) at <10 DSSO, depicting (A) LIVE/DEAD<sup>+</sup>CD3<sup>-</sup>CD19<sup>-</sup>CD56<sup>-</sup> (lin<sup>-</sup>) 193 CD14<sup>+</sup>CD16<sup>-</sup> classical monocytes (cMono), CD14<sup>+</sup>CD16<sup>+</sup> intermediate monocytes (iMono), 194 CD14<sup>-</sup>CD16<sup>+</sup> non-classical monocytes (ncMono), (B) lin<sup>-</sup>CD14<sup>-</sup>CD16<sup>-</sup>CD304<sup>+</sup> plasmacytoid cells 195 196 (pDC) and activated pDCs (MFI of HLA-DR in pDC). Quantification of plasma cytokines in NI (n=17), NP (n=27) and P (n=32) at <10 DSSO by multiplex magnetics bead-based immunoassay. 197 (D) Expression of IRF-7 and ISG-15 in PBMC of NP and P at < 10 DSSO by PCR. Each dot 198 199 represents a different subject. Statistical significance was calculated using Mann-Whitney test or Kruskal-Wallis analysis followed by Dunn post-test and indicated by \*p % 0.05; \*\*p % 0.01; and 200 \*\*\*p % 0.001. DSSO, Days since symptom onset. 201

- 202
- 203

#### 204 Type 1 responses shift to type 3 immunity in long-term carriers

The immune system orchestrates distinct resistance mechanisms depending on the nature 205 of the infectious agent, the site of infection and the time after infection onset. Type 1 immunity, 206 207 mediated by IFN $\gamma$ , NK cells, T helper 1 (Th1) lymphocytes and cytotoxic T cells, is primarily induced in response to intracellular pathogens, such as viruses. We thus analyzed type 1 immune 208 responses in our cohort of long-term carriers. First, we detected lower frequencies of circulating 209 210 NK cells in persistently-infected COVID-19 patients compared to non-persistent ones (Fig. 3A). We also observed that the proportion of circulating naïve CD4<sup>+</sup> was slightly reduced in patients of 211 212 the P group (Fig. 3B). These immunophenotypic alterations were in line with a drop in plasmatic 213 IL-7 (Fig. 3C), as this cytokine contributes to NK cell and naïve/memory T cell development and

It is made available under a CC-BY 4.0 International license .

survival <sup>35</sup>. Additionally, we stimulated total PBMCs in vitro with anti-CD3/CD28 beads in order 214 to analyze the inducible cytokine production by circulating CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Polyclonally-215 activated PBMCs from long-term carriers showed elevated amounts of TNFa produced by T helper 216 cells and Granzyme B by cytotoxic T cells, while the synthesis of these cytokines in the non-217 persistent COVID-19 patients was not different from that of non-infected individuals at this early 218 219 time point ( $\leq$  10 DSSO) (Fig. 3D). Further analysis of systemic hallmarks of type 1 immunity revealed significantly lower IFNy and IL-12 concentrations in the plasma of long-term carriers 220 (Fig. 3E), but higher circulating levels of IL-15, a broadly pleiotropic cytokine with stimulating 221 222 effects on NK cells and T lymphocytes.

Considering the reduced type 1 immunity taking place only in the of patients subsequently 223 evolving towards a persistent infection, we next explored whether long-term carriers presented a 224 functional deviation to type 2 or type 3 immunity. Analysis of plasma cytokines showed that, while 225 type 2-associated cytokines, such as IL-4, IL-13 and IL-9, were poorly represented in the plasma 226 of patients with prolonged infection, the concentration of IL-17A was strongly increased (Fig. 3F, 227 G). Soluble mediators responsible for neutrophil development and recruitment, such as G-CSF, 228 MIP-1 $\alpha$  (CCL4) and IL-8 (CXCL8) were also augmented, indicating a more prominent type 3 229 230 immune profile. These observations suggest a shift from type 1 immunity to type 3 immune responses in patients with persistent SARS-CoV-2 infection. 231

It is made available under a CC-BY 4.0 International license .

232 Fig. 3



It is made available under a CC-BY 4.0 International license .

Figure 3. Dampened type 1 immunity in persistent patients. Immunophenotyping of immune 234 cell populations in PBMC from NI (n=15), NP (n=22) and P (n=27) at <10 DSSO depicting (A) 235 CD3<sup>-</sup>CD56<sup>+</sup> natural killer cells (NK cells), (B) CD19<sup>-</sup>CD3<sup>+</sup> T lymphocytes (CD3), 236 CD4<sup>+</sup>CD27<sup>+</sup>CD45RA<sup>+</sup> naive CD4 T lymphocytes (Naive CD4), and CD8<sup>+</sup>CD27<sup>+</sup>CD45RA<sup>+</sup> naive 237 CD8 T lymphocytes (Naive CD8). (C) Quantification of plasma IL-7 in (n=17), NP (n=27) and P 238 239 (n=32) at <10 DSSO by multiplex magnetics bead-based immunoassay. (D) Frequencies of CD4<sup>+</sup> T lymphocytes producing IFNy, TNF $\alpha$  and IL-6 and CD8<sup>+</sup> T lymphocytes producing IFNy, TNF $\alpha$ 240 and Granzyme B (Grz B) after polyclonal in vitro stimulation with anti-CD3/CD28 beads of 241 242 PBMCs from (n=12), NP (n=11) and P (n=23). Quantification of plasma (E) IFNy, IL-12, IL-15, (F) IL-4, IL-13, IL-9, (G) IL-17A, G-CSF, MIP-1α, and IL-8 in (*n*=17), NP (*n*=27) and P (*n*=32) 243 at <10 DSSO by multiplex magnetic bead-based immunoassay. Statistical significance was 244 calculated using Mann-Whitney test or Kruskal-Wallis analysis followed by Dunn post-test and 245 indicated by \*p % 0.05; \*\*p % 0.01; and \*\*\*p % 0.001. DSSO, Days since symptom onset. 246

247

248

#### 249 Patients developing persistent infection display an early distinct immune signature

Unsupervised cluster analysis of plasma cytokines at  $\leq 10$  DSSO revealed at least two groups of immune mediators that were differentially regulated in patients with normal resolution of infection compared to those with long-term infection (Fig. 4A). Cluster 1, composed of IL-6, IL-8, IL-17A, G-CSF, IL-15 and MIP-1 $\alpha$ , was overrepresented in most long-term carriers, whereas the cytokines from cluster 5, containing IL-9, IL-10, IFN $\gamma$  and IL-12, were reduced. Additionally, we combined plasma cytokine data with immunophenotyping data from the same time points (Fig 4B and Suppl. Fig.4A, B). The correlation matrix of soluble proteins and immune cell subtypes

revealed a positive correlation of effector CD8<sup>+</sup> T cells with Th1 and Th2 cytokines, which, in 257 turn, inversely correlated with the activation of alternative monocytes and pDCs (Fig. 4B). 258 Furthermore, unsupervised cluster analysis on cytokine data by t-Distributed Stochastic Neighbor 259 Embedding (t-SNE) identified four different groups of patients (Suppl. Fig. 4B). All non-infected 260 controls gathered in one cluster, whereas long-term carriers were distributed in three different 261 groups along with non-persistent patients, irrespective of age, gender or comorbidities. Finally, 262 fold change importance analysis performed on NP versus P patients highlighted IL-17A, MIP1a, 263 IL-15, IL-8 and IFNy as the top five cytokines defining SARS-CoV-2 persistency (Fig. 4C). 264 Altogether, bioinformatic analysis strongly suggests that a combination of early blood markers 265 could predict prolonged SARS-CoV-2 infection. 266

It is made available under a CC-BY 4.0 International license .





271	Figure 4. Early immune signature of persistent patients. (A) Heat map of cytokine
272	concentration in serum from NI, NP and P at <10 DSSO measured by multiplex assay. K-means
273	clustering was used to determine cytokine clusters 1-6 (cluster 1, $n = 6$ ; cluster 2, $n = 6$ ; cluster 3,
274	n = 4; cluster 4, $n = 7$ ; cluster 5, $n = 9$ ; cluster 6, $n = 4$ ). (B) Correlation matrix across PBMC
275	immunophenotyping and cytokines concentrations from NI, NP and P at <10 DSSO. Only
276	significant correlations (p<0.05) are represented as dots. Pearson's correlation coefficients from
277	comparisons of cytokine measurements within the same patients are visualized by color intensity.
278	(C) Fold Change importance analysis between NP and P, calculated using the gtools package in
279	R. IL-17A and MIP-1 $\alpha$ have median equals zero in NP, resulting in an infinite fold change, which
280	is represented by the arrow.

281

282

#### 283 Longitudinal immune profiling of patients with prolonged SARS-CoV-2 infection

Next, we analyzed the cytokine dynamics over the course of infection in the patients of our 284 cohort (Fig. 5A, Suppl. Fig. A). Both IFNa and its target chemokine IP-10 progressively decreased 285 over time in long-term carriers. Suppression of IP-10 has been proposed to be a mechanism of 286 pathogen evasion and persistence in different infection models <sup>36</sup>. This trend could also be 287 observed for IFNy, thus ruling out the possibility of a boost of systemic IFN responses leading to 288 final viral clearance from the URT. Other cytokines went through a transient increase during the 289 290 second week after symptom onset and finally dropped by the end of infection. This effect was particularly pronounced for TNFa, IL-12, IL-17A and IL-8, suggesting that these cytokines might 291 292 contribute to SARS-CoV-2 clearance in the absence of efficient type I IFN responses.

It is made available under a CC-BY 4.0 International license .

To visualize the interplay between these cytokines and viral loads, we depicted cytokine 293 concentrations along with Ct values (represented as Ct-<sup>1</sup>) for the eight individual patients with 294 more than three longitudinal samples (Suppl. Fig. 6A). Instead of a unique immune profile, we 295 found distinct cytokine and Ct dynamics. For instance, patient P11 had almost absent type 1 296 immune responses and elevated concentrations of inflammatory and type 3 cytokines at the 297 298 beginning of infection, and only IL-1 RA increased at later time points. Alternatively, patient P8 began with overall lower cytokine concentrations that progressively increased, peaking at the third 299 week after disease onset and shortly before viral clearance. Another illustrative example was 300 301 patient P24, who remained infected by SARS-CoV-2 for the longest period of time (134 DSSO) and displayed strong viral replication during the first two weeks of infection, without evident 302 alterations in plasma cytokine dynamics. Later on, an increase in TNF $\alpha$ , IFN $\gamma$  and IL-8 was 303 apparent, coinciding with the stabilization of viral titers and final viral clearance. These data 304 suggest that each long-term infected individual copes with viral persistence in a different manner. 305 Furthermore, we studied the behavior of different immune populations longitudinally. 306 Generally, the immunophenotypic changes found during the first 10 days of SARS-CoV-2 307 infection were maintained until the virus was cleared from the nasopharynx (Fig. 5B, Suppl. Fig. 308 309 7A). Frequencies of classical, intermediate and non-classical monocytes only returned to control levels at time points where the virus was no longer detectable in the URT, and a similar trend was 310 311 found for dendritic cell activation, monitored by the surface expression of HLA-DR. Additionally, 312 most long-term carriers displayed lower pDC and NK cell frequencies all along the infection period. 313

Finally, in order to determine whether prolonged infection leads to progressive tissue damage, we quantified plasma concentrations of growth factors associated with wound repair

It is made available under a CC-BY 4.0 International license .

- 316 mechanisms. While VEGF concentrations acutely dropped at the second week after symptom
- 317 onset, some patients showed a transient increase in PDGF-BB and basic FGF around this time
- point and stabilized later on, following the same trend as most inflammatory mediators (Fig. 5C,
- 319 Suppl. Fig. 5A). Altogether, these results suggest that prolonged SARS-CoV-2 infection with low
- 320 viral loads does not lead to persistent inflammation or to systemic tissue damage.

It is made available under a CC-BY 4.0 International license .









NP

Ρ

324

NP

Ρ

Figure 5. Longitudinal immune profiling of persistent patients. (A) Weekly longitudinal 325 quantification of plasma cytokines in non-persistent (NP, blue) and persistent (P, red) patients by 326 multiplex immunoassay. (B) Longitudinal immunophenotyping of PBMCs from NP and P 327 depicting frequencies of CD14<sup>+</sup>CD16<sup>-</sup> classical monocytes (cMono) and CD14<sup>-</sup>CD16<sup>+</sup> non-328 classical monocytes (ncMono), mean fluorescence intensity (MFI) of HLA-DR in CD14<sup>-</sup>CD16<sup>-</sup> 329 CD11c<sup>+</sup>CD141<sup>+</sup>(cDC1) and CD14<sup>-</sup>CD16<sup>-</sup>CD11c<sup>+</sup>CD1c<sup>+</sup>(cDC2), and frequencies of CD14<sup>-</sup>CD16<sup>-</sup> 330 CD304<sup>+</sup> plasmacytoid cells (pDC) and CD3-CD56<sup>+</sup> natural killer cells (NK). Filled dots represent 331 individual samples longitudinally collected at different time points until resolution of infection 332 333 from patients positive by qRT-PCR for SARS-CoV-2, while empty dots represent samples from convalescent patients coinciding with the first negative qRT-PCR for SARS-CoV-2. (C) Weekly 334 longitudinal quantification of VEGF and PDGF-BB in NP and P patients by multiplex magnetics 335 bead-based immunoassay. Statistical significance was calculated using Mann-Whitney test or 336 Kruskal-Wallis analysis followed by Dunn post-test and indicated by \*p % 0.05; \*\*p % 0.01; and 337 \*\*\*p % 0.001. DSSO, Days since symptom onset. 338

339

340

#### 341 SARS-CoV-2 persistency favors the generation of Spike-specific neutralizing antibodies

Adequate innate immune activation is essential for the development of antigen-specific adaptive immunity. Therefore, we next evaluated whether the distinct early immune profile that we found in long-term carriers would have consequences for the development of immunological memory. First, we analyzed different memory T cell populations over time. Some patients with persistent infection displayed higher frequencies of effector memory (EM) and terminally differentiated (EMRA) CD4<sup>+</sup> T cells over the course of infection (Fig. 6A, Suppl. Fig. 7A). We

also observed sustained elevated frequencies of circulating central memory (CM) and EM CD8<sup>+</sup> 348 T cells until virus remission in this group of patients. Furthermore, in order to see whether long-349 term carriers were able to develop SARS-CoV-2-specific effector T cells, we isolated PBMCs at 350 the convalescent phase and re-stimulated them in vitro with a pool of peptides spanning the Spike 351 protein of the alpha variant of SARS-CoV-2. The results show no significant differences in actively 352 353 proliferating T cells (Ki67<sup>+</sup>) between control COVID-19 patients and long-term carriers. Cytokine release by CD4<sup>+</sup> and CD8<sup>+</sup> T cells was comparable as well, except from IL-10 production by CD4<sup>+</sup> 354 CD25<sup>+</sup> T cells, which was once again lower in the persistent group (Fig. 6B, C). These results 355 indicate that persistent infection does not interfere with the development of antigen-specific T cell-356 mediated immune memory, and suggest that protective cellular mechanisms against re-infection 357 are not impaired in long-term carriers. 358

Next, we aimed to study the development of antigen-specific humoral responses. We 359 started analyzing follicular helper T cells (T<sub>FH</sub>), as they contribute to humoral immunity by 360 delivering the necessary signals to B cells to enter germinal center and go through class-switch 361 and affinity maturation. Although we did not find changes in the frequencies of circulating CD4<sup>+</sup> 362  $T_{FH}$  cells (Fig. 6D), polyclonal stimulation of PBMCs collected at  $\leq$  14 DSSO revealed that this T 363 364 cell population produced higher amounts of IL-21 in long-term carriers, being this cytokine essential for B cell help (Fig. 6E). Furthermore, we compared the composition of the B cell 365 compartment and the development of humoral responses in patients with normal or delayed 366 367 resolution of infection. We did not observe significantly different frequencies of circulating mature, class-switched B cells, although the proportion of circulating plasmablasts/plasma cells 368 369 dropped in long-term carriers after 14 DSSO (Fig. 6F, Suppl. Fig. 6A). Serological analysis did 370 not identify significant alterations in the production of nucleocapsid (N) protein-specific IgG

It is made available under a CC-BY 4.0 International license .

371 (Suppl. Fig. 8A) or spike protein-specific IgM, IgG and IgA antibodies over time (Fig. 6G, Suppl.

Fig. 8A). However, plasma of long-term carriers displayed higher titers of circulating neutralizing

antibodies against all analyzed SARS-CoV-2 variants three weeks after symptoms onset, and at

least until the patients reached the convalescent phase (Fig. 6H, Suppl. Fig. 8B). These data suggest

- that development of systemic N protein- of spike protein-specific humoral responses do not seem
- to be sufficient for viral clearance during primary SARS-CoV-2 infection, although it may confer
- 377 better protection against re-infection in long-term carriers.
- 378

It is made available under a CC-BY 4.0 International license .

379 Fig. 6



It is made available under a CC-BY 4.0 International license .

### Figure 6. Profiling of cellular and serological adaptive response of persistent patients. (A) 381 Longitudinal immunophenotyping of PBMC from NP and P depicting CD4<sup>+</sup>CD27<sup>-</sup>CD45RA<sup>-</sup> 382 CCR7<sup>+</sup> type 2 effector memory T cells (EM2), CD4<sup>+</sup>CD27<sup>-</sup>CD45RA<sup>+</sup>CCR7<sup>-</sup> terminally 383 differentiated effector memory T cells (EMRA), CD8<sup>+</sup>CD27<sup>+</sup>CD45RA<sup>-</sup>CCR7<sup>+</sup> central memory T 384 cells (CM), and CD8<sup>+</sup>CD27<sup>-</sup>CD45RA<sup>-</sup>CCR7<sup>-</sup> type 1 effector memory T cells (EM1). Filled dots 385 386 represent individual samples longitudinally collected until resolution of infection from NP and P patients positive by qRT-PCR for SARS-CoV-2. Empty dots represent samples from convalescent 387 coinciding with the first negative qRT-PCR for SARS-CoV-2. (B, 388 patients C) Immunophenotyping of SARS-CoV-2 reactive CD4 and CD8 T cells after in vitro stimulation of 389 PBMC from NP (n=11) and P (n=9) after viral clearance with peptides spanning the Spike protein 390 of the alpha variant of SARS-CoV-2. Percentage of (B) CD4+ and CD8<sup>+</sup> cells expressing Ki67, 391 (C) CD4<sup>+</sup> cells expressing TNF $\alpha$ , CD8<sup>+</sup> cells expressing IFN $\gamma$ and Granzyme B (Grz B), and 392 CD4<sup>+</sup>CD25<sup>+</sup> cells expressing IL-10. (D) Longitudinal immunophenotyping of PBMC from NP and 393 P depicting CD3<sup>+</sup>CD4<sup>+</sup>CXCR5<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup>CXCR5<sup>+</sup> follicular T (TFH) cells. (E) Percentage 394 of CD4<sup>+</sup>CXCR5<sup>+</sup> T cells expressing IL-21 after polyclonal *in vitro* stimulation of PBMC from NP 395 (n=11) and P (n=24) at <14 DSSO with anti CD3/CD28 beads. (F) Longitudinal 396 397 immunophenotyping of PBMC from NP (n=7) and P (n=10) depicting CD27<sup>+</sup>CD38<sup>-</sup> switched immunoglobulin (swIg) memory B cells (MBC) and plasmablast/plasma cells (PB/PC). (G) 398 Longitudinal assessment of Spike-specific IgG and IgA antibodies in plasma from P and NP by 399 400 ELISA assay. (H) Titers of neutralizing antibodies against Alpha S1, Beta S1, Gamma RBD, and Kappa RBD variants of SARS-CoV-2 in plasma from NP and P around 21 DSSO and P by the 401 402 time of viral clearance by multiplex neutralization assay. Statistical significance was calculated

It is made available under a CC-BY 4.0 International license .

using Mann-Whitney test or Kruskal-Wallis analysis followed by Dunn post-test and indicated by
\*p % 0.05; \*\*p % 0.01; and \*\*\*p % 0.001. DSSO, Days since symptom onset.

405

#### 406 **DISCUSSION**

Our cohort comprises a group of oligosymptomatic patients with persistent infection who, 407 by definition, have low resistance and high disease tolerance. Here we show that low resistance in 408 these patients is likely due to impaired innate antiviral immunity, as no major defects in adaptive 409 immunity were found. Furthermore, we observed divergent cytokine profiles systemically and in 410 the nasopharyngeal mucosa, in line with other studies recently published <sup>37</sup>. Major differences in 411 cytokines, chemokines and growth factors were found in the plasma of patients with prolonged 412 413 course of infection early after disease onset. However, although relevant mucosal cytokines, such as IL-17A and IL-10, were not altered in the nasopharynx, we cannot exclude the contribution of 414 415 cytokines with only transient induction or other mucosal mediators not studied here.

416

Systemically, long-term carriers displayed decreased frequencies of circulating classical 417 418 monocytes and pDCs shortly after symptom onset, being the latter essential for the control of viral replication through the rapid release of IFN-I <sup>31,32,38</sup>. Early IFN-I triggers different mechanisms 419 targeting virally infected cells, namely the expression of antiviral proteins, the activation of NK 420 cells and the initiation of Th1 responses. Each one of these elements was underrepresented in those 421 422 COVID-19 patients who later on presented persistent infection. Thus, our data suggest that early systemic immunological patterns may indicate future persistency of SARS-CoV-2 infection in 423 424 immunocompetent patients.

It is made available under a CC-BY 4.0 International license .

Moreover, long-term carriers displayed an immunological shift characterized by a low 426 systemic Th1/2 signature, increasing in turn IL-17A, IL-8 and other neutrophil-recruiting 427 chemokines. In line with our data, mouse models of chronic infection by TMEV also link Th17 428 cells to viral persistence <sup>39</sup>. Impaired IFN-I responses and an enhanced type 3 signature are traits 429 that had been previously associated with severe COVID-19<sup>9-11</sup>. Conversely, inflammatory and 430 Th1/2 responses are elevated in patients with severe symptoms but low in oligosymptomatic long-431 term carriers, which suggests their involvement in the pathogenesis of COVID-19<sup>7–9,13</sup>. Further 432 studies to better characterize the correlation of these immunological patterns with infectious 433 disease outcome are warranted. 434

435

The engagement of disease tolerance mechanisms, like enhanced tissue repair, metabolic 436 adaptations or immune regulation, may also lead to distinct disease trajectories <sup>40,41</sup>. Our data could 437 not identify enhanced systemic tissue repair or regulatory responses during the course of prolonged 438 SARS-CoV-2 infection. The immunoregulatory cytokine IL-10, which is commonly linked to 439 immunological tolerance, but also a well-accepted disease marker in COVID-19<sup>42,43</sup>, was 440 particularly low in long-term carriers. In order to understand the physiological meaning of this 441 442 effect and the involvement of additional disease tolerance mechanisms, further analysis should be conducted. 443

444

In our study, long-term SARS-CoV-2 carriers had higher titers of neutralizing Spikespecific antibodies already three weeks after symptom onset. First, this indicates that systemic neutralizing antibodies are not sufficient for viral clearance from the URT during primary infection. Type I IFNs may contribute to this effect, since they have been associated with

It is made available under a CC-BY 4.0 International license .

modulation of B cell responses and antibody production in the context of viral infection <sup>44,45</sup>. 449 Furthermore, patients with severe COVID-19, who may remain infected for extended time periods 450 and present dysregulated IFN-I and type 3 responses, have also been shown to produce higher 451 titers of neutralizing antibodies <sup>46</sup>. Together with our data, this suggests that dampened IFN-I 452 responses and/or strong type 3 immunity in persistent SARS-CoV-2 infection might confer 453 454 advantages against re-infection. On the other hand, these antibodies might also contribute to viral persistence via antibody-dependent enhancement or modulate COVID-19 immunopathology via 455 Fc-receptors. Hence, analysis of the functionality of the antibodies elicited during long-term 456 infection, and longer follow-up of the adaptive cellular and humoral immunity in these patients 457 could be valuable for COVID-19 treatment and vaccine design and development. 458

459

Given the out-care characteristic of our cohort and the techniques available, our 460 investigation of viral RNA was restricted to nasopharyngeal samples. Assessment of viral titers in 461 various tissues would allow for a better understanding of whether long-term carriers display 462 systemic low resistance, or if this phenomenon is restricted to the mucosal site. Although we did 463 not find increased damage and tissue repair markers in the blood or in the nasal mucosa, we cannot 464 465 exclude that other SARS-CoV-2 target tissues, such as the lungs or the gut, have altered disease tolerance or support viral replication. To study disease tolerance and viral presence in such 466 467 locations, animal models for SARS-CoV-2 would be helpful. Furthermore, our samples are limited 468 and were collected in a specific timing and geographical context of the pandemic. Nonetheless, to our knowledge, the present study constitutes the characterization of immune parameters in the 469 470 larger number of immunocompetent oligosymptomatic patients with persistent infection of SARS-

It is made available under a CC-BY 4.0 International license .

471 CoV-2 so far. Still, sample size is critical when studying such a heterogeneous disease as COVID-

- 472 19, and, therefore, validation of our data in larger, independent cohorts would be informative.
- 473

Collectively, our study provides a thorough analysis of the immune dynamics during viral 474 persistency in COVID-19 patients. Over the past two years, important progress has been made in 475 476 controlling the pandemic, but the vaccines available, though successful in limiting disease, are not sterilizing and do not completely prevent transmission of new SARS-CoV-2 variants <sup>47</sup>. In 477 COVID-19 as well as in other viral infections, oligosymptomatic and asymptomatic carriers 478 represent the main vector of viral transmission. Therefore, long-term immunocompetent infected 479 individuals are potential long-term spreaders and may, additionally, facilitate intra-host evolution 480 of SARS-CoV-2 and other viruses <sup>17,22,23</sup>. This reinforces the need for a better understanding of 481 the immune mechanisms of viral control in these patients. All in all, our study identifies a set of 482 early plasma markers associated with prolonged infection and reveals alternative immunological 483 strategies to deal with viral infection without major tissue damage. 484

485

486

487 Acknowledgments: This work was partially supported by ANRS | Maladies infectieuses émergentes/INSERM grant (MUCOVID-007) (to DK and MTB); by CAPES, Edital de Seleção 488 489 Emergencial II CAPES grant 88887.507381/2020-00 (to MTB); by Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), grant E-26/201.128/2022 (272688) and E-490 491 26/211.564/2019 (252360) (to MTB), E-26/010.002434/2019 and E-26/210.178/2020 (to AT), E-26/203.002/208 (to A.M.V.); by Conselho Nacional de Desenvolvimento Científico e Tecnológico 492 493 (CNPq) grant 312477/2021-0 (to MTB) and grants 439649/2018-8 and 316796/2021-2 (to A.M.V.); Instituto Serrapilheira (to AT). 494

495 EM-C; VCB; GSL; VAO were supported by fellowships from CAPES (88887.507381/2020-00).

It is made available under a CC-BY 4.0 International license .

- 496 CM; CC; LC were supported by fellowships from FAPERJ
- 497 DASR was supported by a fellowship from CNPq (DTI-A; 401209/2020-2).
- 498 ICL was supported by a fellowship from CNPq
- 499 JCRF and LZR were supported by fellowships from ANRS/INSERM (MUCOVID-007)
- 500 HDRF; CSC; VMV; AMS were supported by fellowships from CAPES
- 501

#### 502 Author contributions:

- 503 Conceptualization: EM-C; VCB; CM; AT; DK; AMV; TMC; JE-L; MTB
- 504 Methodology: EM-C; VCB; CM; JE-L; MTB
- 505 Investigation: EM-C; VCB; CM; JCRF; HDRF; CSC; DASR; AMS; VMV; LSA; LZR; GSL;
- 506 VAO; CC; LC; ICL; JE-L
- 507 Formal analysis: EM-C; VCB; CM; JCRF; CC; DASR; RMP; AMV; JE-L; MTB
- 508 Visualization: EM-C; VCB; JE-L; MTB
- 509 Funding acquisition: AT; DK; AMV; TMC; MTB
- 510 Project administration: EM-C; AT; AMV; TMC; JE-L; MTB
- 511 Supervision: EM-C; AT, OCF; AMV; TMC; JE-L; MTB
- 512 Writing original draft: EM-C; VCB; CM; DK; JE-L; MTB
- 513 Writing review & amp; editing: EM-C; VCB; CM; AT; OCF; RMP; DK; AMV; TMC; JE-L;
- 514 MTB
- 515
- 516 **Competing interests:** Authors declare that they have no competing interests
- 517
- 518
- 519
- 520
- 521 STAR Methods

It is made available under a CC-BY 4.0 International license .

#### 522 Cohort and Study Design

All patients included in the present study sought testing at the Diagnostic Screening Center 523 for COVID-19 at the Federal University of Rio de Janeiro (CTD-UFRJ) and declared written 524 informed consent. From April to December 2020, we enrolled two thousand seven hundred and 525 fifty-nine patients who were tested for SARS-CoV-2 infection at the Diagnostic Screening Center 526 for COVID-19 of the Federal University of Rio de Janeiro (CTD-UFRJ). Among them, 1,133 527 528 individuals (41.07%) tested positive for the presence of SARS-CoV-2 RNA by quantitative PCR with reverse transcription (RT-qPCR) on nasopharyngeal swab samples. Those individuals were 529 offered weekly follow-up testing until SARS-CoV-2 RNA was no longer detected. Blood from 530 531 those patients was collected in heparinized tubes for plasma and PBMC storage and further analysis. Symptoms, use of medication, comorbidities and demographic information were assessed 532 by oral questionnaire performed by trained personnel. Based on blood sample availability, 33 533 patients were selected from those with persistent SARS-CoV-2 infection, defined as positive 534 SARS-CoV-2 RT-qPCR in upper respiratory tract (URT) samples after 21 days after symptom 535 onset. As such, 32 patients were selected from those who did not display persistent viral RNA, 536 defined as a negative SARS-CoV-2 RT-qPCR in URT samples up to 21 days after symptom onset. 537 538 The criterion was guided by the median of positivity duration in the overall cohort, which was 539 around three weeks (Voloch et al, 2021). Twenty-five non-infected volunteers were included as controls, defined as a negative SARS-CoV-2 qRT-PCR, no history of a positive SARS-CoV-2 540 qRT-PCR and no seroconversion for SARS-CoV-2 epitopes. All procedures and experiments were 541 542 approved by the correspondent Ethic Committee Board (CAAE: 30161620.0.1001.5257; 4.245.490). 543

It is made available under a CC-BY 4.0 International license .

#### 545 **PBMC and plasma isolation**

PBMCs were isolated from blood collected in lithium heparin tubes by Ficoll-Hypaque 546 density gradient centrifugation. Briefly, blood was layered on a density gradient (Hystopaque® 547 1077, Sigma-Aldrich), and PBMCs were separated by centrifuging at 400 rcf for 30 min. PBMCs 548 were washed four times in phosphate-buffered saline (PBS), submitted to ACK for 5 min to lysate 549 red blood cells, and frozen in liquid nitrogen in 90% fetal bovine serum (FBS) with 10% DMSO 550 551 (Sigma-Aldrich) until used for flow cytometry and stimulation assays. Plasma samples were collected in 10-ml tubes in lithium heparin tubes, centrifuged at 400 rcf for 10 min, aliquoted, and 552 stored at  $-20^{\circ}$ C for further experiments. 553

554

#### 555 Cell culture

PBMCs were thawed in RPMI 1640 medium (Lonza) supplemented with 10% FBS 556 (Gibco<sup>TM</sup>) and penicillin (100 IU/ml; Gibco<sup>TM</sup>)/streptomycin (100 µg/ml; Gibco<sup>TM</sup>). For T cell 557 stimulation, 0.5×10<sup>6</sup> PBMCs were cultured in 500µl of medium in a 24-well flat-bottomed 558 microplate and stimulated for 4 days with anti-CD3/anti-CD28 Dynabeads<sup>TM</sup> Human T-activator 559 (10 µL/mL, Gibco<sup>™</sup>). For detection of SARS-CoV-2–specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells, 0.5×10<sup>6</sup> 560 PBMC cells were stimulated in a 96-well U-bottom plate for 7 days in 200 ul of medium containing 561 1 µg/ml of SARS-CoV-2 variant Spike peptide pools (JPT Peptide Technologies) in the presence 562 of IL-2r (20UI, PrepoTech Inc.). As a control, some cells were maintained with IL-2r alone. After 563 6 days, the cells were re-stimulated with 10µg/ml of the aforementioned peptide pools overnight. 564 In order to optimize the detection of intracellular cytokines, Brefeldin A (10 µg/mL; BD 565 Biosciences, San Diego, CA, USA) was added in the last 4 h (for Dynabeads<sup>TM</sup>) or 12h (for SARS-566 CoV-2 peptide pools) of the cell cultures. Cultures were maintained in a humidified incubator with 567

It is made available under a CC-BY 4.0 International license .

568 5% CO2 at 37°C. After stimulation, cells were stained for proliferation and/or phenotypic 569 lymphocyte markers by Flow Cytometry.

570

#### 571 Flow Cytometry

Staining for flow cytometry analysis was performed using fluorescently-labeled specific 572 anti-human antibodies. Unless otherwise stated, antibodies were purchased from Biolegend: IgD-573 PE-Cy7. CD15-BV421, CD56-PE-CF594, CD14-PECy5, CD16-BV786, 574 HLA-DR-BB515/PECy5 (BD Bioscience), CD11b-APC-Cy7, CD304-PE, CD11c-BV711, CD1c-APC, 575 CD141-BV650, CD3-BV510/BV605, CD4-BV785, CD19-BV421/BV510, CD8-BV711/APC-576 Fire750, CD27-FITC/PE, CCR7-BV421, CD45RA-PE-Cy7/PE-Cy5, CD25-AF700, PD-1-PE, 577 CD38-BV711/PE-Cy5, CXCR5-PE-CF594, Ki67-APC, IL-10-BV421, Granzyme B-FITC (BD 578 Bioscience), IFNγ-APC-Fire750, TNFα-BV650, IL-9-PE, IL-6-PE/PE-Cy7, and IL-21-PerCP-579 Cy5.5. 580

Briefly, 5x10<sup>5</sup> cells were incubated with LIVE/DEAD Fixable Aqua Dead Cell staining 581 (1:1000, BV510; Invitrogen) in PBS for 30 min, and washed with PBS containing 3% FBS and 582 0.01% sodium azide. Next, cells were incubated with the fluorescently-labelled antibodies for 30 583 min at room temperature in the dark. When intracellular staining was required, cells were 584 permeabilized with the Cytofix/Cytoperm solution (BD Pharmigen) at 4°C for 20 min and 585 subsequently incubated for 30 min at 4°C with the appropriate antibodies. Events were acquired 586 on LSR FORTESSA X-20 (BD Biosciences). Target cells were gated based on forward and side 587 scatter properties, singlets and living cells were analyzed by using FlowJo<sup>©</sup> Software. FMO 588 controls and single-stained samples were used to periodically check the settings and gates on the 589 flow cytometer. 590

It is made available under a CC-BY 4.0 International license .

591

#### 592 Quantification of inflammatory, anti-inflammatory, and antiviral mediators

Cytokines and immune mediators were quantified with a multiplex magnetic bead-based 593 immunoassay according to the manufacturer's instructions, using the Bio-Plex Pro<sup>™</sup> Human 594 595 Cytokines 27-Plex Assay (BIO-RAD) and the Human ProcartaPlexTM kit (Invitrogen<sup>™</sup>, 596 ThermoFisher Scientific), including the following analytes: basic FGF, Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-597 17A, IP-10/CXCL10, MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4, PDGF-BB, TNF-α, and 598 599 VEGF, IFNα, IFNβ, IFNΩ, IL-29, IL-18, IL-21, syndecan, ferritin. Data were acquired in a Luminex MAGIPIX® System (serial number MAGPX11266003) using the XPONENT software. 600 Additionally, IL-6, and RANTES/CCL5 concentrations were determined in plasma samples by 601 enzyme-linked immunosorbent assay (Human IL-6 and RANTES/CCL5 TMB ELISA, 602 Peprotech), according to the manufacturer's instructions. Absorbance was measured in a 603 SpectraMax<sup>®</sup> microplate reader (Molecular Device). 604

605

#### 606 **Quantitative PCR**

RNA from PBMCs was extracted using Fastzol (QuatroG, Brazil), according to the
manufacturer's instructions. 1µg of RNA was reverse transcribed to complementary DNA (cDNA)
with the High-Capacity RNA-to-cDNA<sup>TM</sup> Kit (Applied Biosystems<sup>TM</sup>) and random primers.
Quantitative RT-PCR was performed with the Power SYBR<sup>®</sup> Green PCR Master Mix (Applied
Biosystems<sup>TM</sup>) in an ABI 7500 instrument (Applied Biosystems<sup>TM</sup>). Ct values were normalized to

It is made available under a CC-BY 4.0 International license .

612 the mRNA expression of GAPDH and relative expression was calculated with the  $\Delta\Delta$ Ct method.

613 Primer sequences are available upon request.

614

#### 615 Determination of SARS-CoV-2 specific immunoglobulins and neutralizing antibodies

Anti-SARS-CoV-2 spike protein IgM, IgA, and IgG antibodies were quantified by enzyme-616 linked immunosorbent assay, following the S-UFRJ test protocol, as previously described <sup>48</sup>. 617 Briefly, serial dilutions of plasma samples (starting 1:40, in PBS 1% BSA) were incubated in high-618 binding ELISA plates previously coated with 50 µL of SARS-CoV-2 spike protein (4 µg/mL) 619 overnight. Antibodies were detected with goat anti-human IgG, IgA, and IgM (Fc)-horseradish 620 peroxidase antibodies (Southern Biotech) and developed with TMB (Scienco). Optical density 621 (OD) was measured in a SpectraMax® microplate reader (Molecular Device, USA). Plasma titers 622 of neutralizing antibodies were quantified with a multiplex magnetic bead-based immunoassay, 623 using the Bio-Plex Pro Human SARS-CoV-2 Neutralization Antibody Assay (BIO-RAD) 624 according to the manufacturer's instructions. 625

626

#### 627 Statistical analysis

One-dimensional probability distributions of samples were analyzed by Kolmogorov– Smirnov test. Statistical analysis was performed by one-way variance analysis followed by Bonferroni post-test for samples with normal distribution; or Kruskal-Wallis analysis followed by Dunn post-test. Correlations were analyzed by Spearman's rank correlation coefficient. The statistical analysis was performed using Prism 8.0 software (GraphPad Software, San Diego, CA).

It is made available under a CC-BY 4.0 International license .

It is made available under a CC-BY 4.0 International license .

## 634 Supplementary Material

#### 635 Suppl. Fig. 1.



It is made available under a CC-BY 4.0 International license .

#### 637 Suppl. Fig. 1. Cytokine analysis in swab samples at disease onset. Cytokine quantification in

- 638 swabs samples from upper respiratory tract of NP (n=9) and P (n=13) at <10 DSSO by multiplex
- 639 magnetics bead-based immunoassay. Each dot represents a subject. Filled dots represent a positive
- 640 qRT-PCR of nasopharyngeal samples for SARS-CoV-2. Statistical significance was calculated
- 641 using Mann-Whitney test.

It is made available under a CC-BY 4.0 International license .

## 643 Suppl. Fig. 2.



It is made available under a CC-BY 4.0 International license .

## 645 Suppl. Fig. 2. Flow cytometry gating strategies. Gating strategies on PBMCs for

646 immunophenotyping of (A) innate immune cells, among them NK cells, monocytes and dendritic

cells, (B) T lymphocytes and (C) B lymphocytes.

It is made available under a CC-BY 4.0 International license .

## 649 Suppl. Fig. 3.



It is made available under a CC-BY 4.0 International license .

652	Suppl. Fig. 3. Immunophenotyping and plasma cytokine analysis at disease onset.
653	Immunophenotyping of major innate immune cell populations in PBMC (A) LIVE/DEAD <sup>-</sup> CD3 <sup>-</sup>
654	CD19 <sup>-</sup> CD56 <sup>-</sup> (lin <sup>-</sup> ) CD14 <sup>-</sup> CD16 <sup>-</sup> CD11c <sup>+</sup> CD141 <sup>+</sup> type 1 dendritic cells (cDC1), LIVE/DEAD <sup>-</sup> lin <sup>-</sup>
655	CD14 <sup>-</sup> CD16 <sup>-</sup> CD11c <sup>+</sup> CD1c <sup>+</sup> type 2 dendritic cells (cDC2) and LIVE/DEAD <sup>-</sup> lin <sup>-</sup> HLA <sup>-</sup> DR <sup>-</sup> CD14 <sup>+</sup>
656	myeloid-derived suppressor cells (MoMDSCs). (B) MFI of HLA-DR in cMono, iMono, ncMono,
657	cDC1 and cDC2 cell populations. (C) Quantification of plasma cytokines in non-infected
658	individuals (NI), non-persistent patients (NP) and persistent patients (P) at <10 DSSO by multiplex
659	magnetics bead-based immunoassay. Each dot represents a different subject. Statistical
660	significance was calculated using Mann-Whitney test or Kruskal-Wallis analysis followed by
661	Dunn post-test and indicated by *p % 0.05; **p % 0.01; and ***p % 0.001. DSSO, Days since
662	symptom onset.

It is made available under a CC-BY 4.0 International license .

## 664 Suppl. Fig. 4



В



○ NI ○ NP ○ P

It is made available under a CC-BY 4.0 International license .

#### 666 Suppl. Fig. 4. Cluster analysis of immunophenotyping and plasma cytokine data at disease

- 667 onset. (A) Heat map of blood cell populations and cytokine concentration in serum from P, NP
- and NI at <10 DSSO measured by flow cytometry and Luminex assay. K-means clustering was
- 669 used to determine cytokine clusters 1-7). Measurements were normalized across all patients by Z-
- 670 score. (B) t-Distributed Stochastic Neighbor Embedding (t-SNE) probabilistic dimensionality
- reduction technique applied in PBMC immunophenotyping and cytokines concentration at <10
- DSSO from 51 patients (P, Blue, n=27; NP, Orange, n=19; NI, Green, n=5). Measurements were
- 673 normalized across all patients by Z-score.
- 674

It is made available under a CC-BY 4.0 International license .

675 **Suppl. Fig. 5.** 



676

Suppl. Fig. 5. Longitudinal cytokine analysis. (A) Weekly longitudinal quantification of plasma
cytokines in non-persistent (NP, blue) and persistent (P, red) patients by multiplex magnetics beadbased immunoassay.

It is made available under a CC-BY 4.0 International license .

#### 681 Suppl. Fig. 6



Suppl. Fig. 6. Longitudinal analysis of plasma cytokine and viral loads in individual patients. (A) Longitudinal depiction of plasma IFNα, IP-10, TNFα, IL-1β, IL-12, IFNγ, IL-4, IL-9, IL-17A and IL-8 and viral loads in individual patients with persistent infection and at least three longitudinal samples available. Ct values (depicted as  $Ct^{-1}$ ) were determined by qRT-PCR of viral RNA on nasopharyngeal swab samples. Cytokine concentrations were measured by multiplex magnetics bead-based immunoassay.

It is made available under a CC-BY 4.0 International license .

It is made available under a CC-BY 4.0 International license .

## 690 Suppl. Fig. 7



692	Suppl. Fig. 7. Longitudinal analysis of immune cell populations. Longitudinal
693	immunophenotyping in PBMC of NP and P patients. Filled dots represent individual samples
694	longitudinally collected at different time points until resolution of infection from patients positive
695	by qRT-PCR for SARS-CoV-2, while empty dots represent samples from convalescent patients
696	coinciding with the first negative qRT-PCR for SARS-CoV-2. Statistical significance was
697	calculated using Mann-Whitney test or Kruskal-Wallis analysis followed by Dunn post-test and
698	indicated by *p % 0.05; **p % 0.01; and ***p % 0.001.

It is made available under a CC-BY 4.0 International license .

#### Suppl. Fig. 8 700

Α









В





It is made available under a CC-BY 4.0 International license .

702

703	Suppl. Fig. 8. Longitudinal analysis of SARS-CoV-2-specific immunoglobulins and
704	neutralizing antibodies. Longitudinal assessment of anti-N IgG and anti-S IgM antibodies in
705	plasma from P and NP by ELISA assay. (H) Titers of neutralizing antibodies against S1, D614G
706	S1, RBD, Epsilon RBD, K417N RBD, E484K RBD, and N501Y RBD variants of SARS-CoV-2
707	in plasma from NP and P around 21 DSSO and P by the time of viral clearance by competitive
708	Luminex multiplex neutralization assay. Statistical significance was calculated using Mann-
709	Whitney test or Kruskal-Wallis analysis followed by Dunn post-test and indicated by *p % 0.05;
710	**p % 0.01; and ***p % 0.001. DSSO, Days since symptom onset.
711	

It is made available under a CC-BY 4.0 International license .

#### 713 **References**

- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Lond. Engl. 395, 497–506. 10.1016/S0140-6736(20)30183-5.
- 717 2. Liu, L., Lei, X., Xiao, X., Yang, J., Li, J., Ji, M., Du, W., Tan, H., Zhu, J., Li, B., et al.
- (2020). Epidemiological and Clinical Characteristics of Patients With Coronavirus Disease 2019 in Shiyan City, China. Front. Cell. Infect. Microbiol. *10*.
- Nogrady, B. (2020). What the data say about asymptomatic COVID infections. Nature 587,
   534–535. 10.1038/d41586-020-03141-3.
- 4. He, X., Lau, E.H.Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y.C., Wong, J.Y., Guan, Y.,
  Tan, X., et al. (2020). Temporal dynamics in viral shedding and transmissibility of COVID19. Nat. Med. 26, 672–675. 10.1038/s41591-020-0869-5.
- Verity, R., Okell, L.C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P.G.T., Fu, H., et al. (2020). Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect. Dis. 20, 669– 677. 10.1016/S1473-3099(20)30243-7.
- 6. Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., Curtis,
  H.J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020). Factors associated with COVID-19related death using OpenSAFELY. Nature *584*, 430–436. 10.1038/s41586-020-2521-4.
- Giamarellos-Bourboulis, E.J., Netea, M.G., Rovina, N., Akinosoglou, K., Antoniadou, A.,
   Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020).
   Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.
   Cell Host Microbe 27, 992-1000.e3. 10.1016/j.chom.2020.04.009.
- Mathew, D., Giles, J.R., Baxter, A.E., Oldridge, D.A., Greenplate, A.R., Wu, J.E., Alanio,
   C., Kuri-Cervantes, L., Pampena, M.B., D'Andrea, K., et al. (2020). Deep immune profiling
   of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science.
   10.1126/science.abc8511.
- Lucas, C., Wong, P., Klein, J., Castro, T.B.R., Silva, J., Sundaram, M., Ellingson, M.K.,
  Mao, T., Oh, J.E., Israelow, B., et al. (2020). Longitudinal analyses reveal immunological
  misfiring in severe COVID-19. Nature *584*, 463–469. 10.1038/s41586-020-2588-y.
- 10. Bastard, P., Rosen, L.B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham,
  K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020). Autoantibodies against type I IFNs in
  patients with life-threatening COVID-19. Science *370*, eabd4585. 10.1126/science.abd4585.
- 11. Lopez, J., Mommert, M., Mouton, W., Pizzorno, A., Brengel-Pesce, K., Mezidi, M., Villard,
  M., Lina, B., Richard, J.-C., Fassier, J.-B., et al. (2021). Early nasal type I IFN immunity
  against SARS-CoV-2 is compromised in patients with autoantibodies against type I

It is made available under a CC-BY 4.0 International license .

- 749 IFNsImpact of nasal IFN-I autoantibodies in COVID-19. J. Exp. Med. *218*, e20211211.
   750 10.1084/jem.20211211.
- 12. Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli,
  I.K.D., Hodeib, S., Korol, C., et al. (2020). Inborn errors of type I IFN immunity in patients
  with life-threatening COVID-19. Science *370*, eabd4570. 10.1126/science.abd4570.
- 13. Bergamaschi, L., Mescia, F., Turner, L., Hanson, A.L., Kotagiri, P., Dunmore, B.J.,
  Ruffieux, H., Sa, A.D., Huhn, O., Morgan, M.D., et al. (2021). Longitudinal analysis reveals
  that delayed bystander CD8+ T cell activation and early immune pathology distinguish
  severe COVID-19 from mild disease. Immunity *54*, 1257-1275.e8.
  10.1016/j.immuni.2021.05.010.
- 14. Bost, P., Giladi, A., Liu, Y., Bendjelal, Y., Xu, G., David, E., Blecher-Gonen, R., Cohen, M.,
  Medaglia, C., Li, H., et al. (2020). Host-viral infection maps reveal signatures of severe
  COVID-19 patients. Cell, S0092867420305687. 10.1016/j.cell.2020.05.006.

15. Schneider, D., and Ayres, J. (2008). Two ways to survive infection: what resistance and
tolerance can teach us about treating infectious diseases. Nat. Rev. Immunol. 8.
10.1038/nri2432.

- 16. Medzhitov, R., Schneider, D.S., and Soares, M.P. (2012). Disease Tolerance as a Defense
  Strategy. Science *335*, 936–941. 10.1126/science.1214935.
- 17. Choi, B., Choudhary, M.C., Regan, J., Sparks, J.A., Padera, R.F., Qiu, X., Solomon, I.H.,
  Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020). Persistence and Evolution of SARSCoV-2 in an Immunocompromised Host. N. Engl. J. Med. *383*, 2291–2293.
  10.1056/NEJMc2031364.
- 18. Avanzato, V.A., Matson, M.J., Seifert, S.N., Pryce, R., Williamson, B.N., Anzick, S.L.,
  Barbian, K., Judson, S.D., Fischer, E.R., Martens, C., et al. (2020). Case Study: Prolonged
  Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual
  with Cancer. Cell *183*, 1901-1912.e9. 10.1016/j.cell.2020.10.049.
- 19. Tarhini, H., Recoing, A., Bridier-Nahmias, A., Rahi, M., Lambert, C., Martres, P., Lucet, J.C., Rioux, C., Bouzid, D., Lebourgeois, S., et al. (2021). Long-Term Severe Acute
  Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three
  Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2
  Superinfection. J. Infect. Dis. *223*, 1522–1527. 10.1093/infdis/jiab075.
- Truong, T.T., Ryutov, A., Pandey, U., Yee, R., Goldberg, L., Bhojwani, D., Aguayo-Hiraldo,
  P., Pinsky, B.A., Pekosz, A., Shen, L., et al. (2021). Increased viral variants in children and
  young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A
  consecutive case series. eBioMedicine 67. 10.1016/j.ebiom.2021.103355.

Ayres, J.S. (2020). Surviving COVID-19: A disease tolerance perspective. Sci. Adv. 6,
 eabc1518. 10.1126/sciadv.abc1518.

It is made available under a CC-BY 4.0 International license .

- Voloch, C.M., F, R. da S., Almeida, L.G.P. de, Brustolini, O.J., Cardoso, C.C., Gerber, A.L.,
  Guimarães, A.P. de C., Leitão, I. de C., Mariani, D., Ota, V.A., et al. (2020). Intra-host
  evolution during SARS-CoV-2 persistent infection 10.1101/2020.11.13.20231217.
- 23. Leitão, I. de C., Calil, P.T., Galliez, R.M., Moreira, F.R.R., Mariani, D., Castiñeiras, A.C.P.,
  da Silva, G.P.D., Maia, R.A., Corrêa, I.A., Monteiro, F.L.L., et al. (2021). Prolonged SARSCoV-2 Positivity in Immunocompetent Patients: Virus Isolation, Genomic Integrity, and
  Transmission Risk. Microbiol. Spectr. *9*, e0085521. 10.1128/Spectrum.00855-21.
- Murata, T., Sakurai, A., Suzuki, M., Komoto, S., Ide, T., Ishihara, T., and Doi, Y. Shedding
  of Viable Virus in Asymptomatic SARS-CoV-2 Carriers. mSphere 6, e00019-21.
  10.1128/mSphere.00019-21.
- 25. Owusu, D., Pomeroy, M.A., Lewis, N.M., Wadhwa, A., Yousaf, A.R., Whitaker, B.,
  Dietrich, E., Hall, A.J., Chu, V., Thornburg, N., et al. (2021). Persistent SARS-CoV-2 RNA
  Shedding Without Evidence of Infectiousness: A Cohort Study of Individuals With COVID19. J. Infect. Dis. 224, 1362–1371. 10.1093/infdis/jiab107.
- 26. Heyer, A., Günther, T., Robitaille, A., Lütgehetmann, M., Addo, M.M., Jarczak, D., Kluge,
  S., Aepfelbacher, M., Wiesch, J.S. zur, Fischer, N., et al. (2022). Remdesivir-induced
  emergence of SARS-CoV2 variants in patients with prolonged infection. Cell Rep. Med. *3*.
  10.1016/j.xcrm.2022.100735.
- Liu, W.-D., Chang, S.-Y., Wang, J.-T., Tsai, M.-J., Hung, C.-C., Hsu, C.-L., and Chang, S.-C. (2020). Prolonged virus shedding even after seroconversion in a patient with COVID-19.
  J. Infect. *81*, 318–356. 10.1016/j.jinf.2020.03.063.
- 28. Widders, A., Broom, A., and Broom, J. (2020). SARS-CoV-2: The viral shedding vs
  infectivity dilemma. Infect. Dis. Health 25, 210–215. 10.1016/j.idh.2020.05.002.
- Vibholm, L.K., Nielsen, S.S.F., Pahus, M.H., Frattari, G.S., Olesen, R., Andersen, R.,
  Monrad, I., Andersen, A.H.F., Thomsen, M.M., Konrad, C.V., et al. (2021). SARS-CoV-2
  persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine *64*,
  103230. 10.1016/j.ebiom.2021.103230.
- 30. Drénou, B., Amiot, L., Setterblad, N., Taque, S., Guilloux, V., Charron, D., Fauchet, R., and
  Mooney, N. (2005). MHC class II signaling function is regulated during maturation of
  plasmacytoid dendritic cells. J. Leukoc. Biol. 77, 560–567. 10.1189/jlb.0704423.
- S1. Cervantes-Barragan, L., Züst, R., Weber, F., Spiegel, M., Lang, K.S., Akira, S., Thiel, V.,
  and Ludewig, B. (2006). Control of coronavirus infection through plasmacytoid dendriticcell–derived type I interferon. Blood *109*, 1131–1137. 10.1182/blood-2006-05-023770.
- 32. Severa, M., Diotti, R.A., Etna, M.P., Rizzo, F., Fiore, S., Ricci, D., Iannetta, M., Sinigaglia,
  A., Lodi, A., Mancini, N., et al. (2021). Differential plasmacytoid dendritic cell phenotype
  and type I Interferon response in asymptomatic and severe COVID-19 infection. PLOS
  Pathog. *17*, e1009878. 10.1371/journal.ppat.1009878.
  - 54

- 33. Jamieson, A.M., Pasman, L., Yu, S., Gamradt, P., Homer, R.J., Decker, T., and Medzhitov,
  R. (2013). Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science *340*, 1230–1234. 10.1126/science.1233632.
- 34. Piotti, A., Novelli, D., Meessen, J.M.T.A., Ferlicca, D., Coppolecchia, S., Marino, A., Salati,
  G., Savioli, M., Grasselli, G., Bellani, G., et al. (2021). Endothelial damage in septic shock
  patients as evidenced by circulating syndecan-1, sphingosine-1-phosphate and soluble VEcadherin: a substudy of ALBIOS. Crit. Care 25, 113. 10.1186/s13054-021-03545-1.
- 35. Chen, D., Tang, T.-X., Deng, H., Yang, X.-P., and Tang, Z.-H. (2021). Interleukin-7 Biology
  and Its Effects on Immune Cells: Mediator of Generation, Differentiation, Survival, and
  Homeostasis. Front. Immunol. *12*.
- 36. Antonia, A.L., Gibbs, K.D., Trahair, E.D., Pittman, K.J., Martin, A.T., Schott, B.H., Smith,
  J.S., Rajagopal, S., Thompson, J.W., Reinhardt, R.L., et al. (2019). Pathogen Evasion of
  Chemokine Response Through Suppression of CXCL10. Front. Cell. Infect. Microbiol. 9.
- Smith, N., Goncalves, P., Charbit, B., Grzelak, L., Beretta, M., Planchais, C., Bruel, T.,
  Rouilly, V., Bondet, V., Hadjadj, J., et al. (2021). Distinct systemic and mucosal immune
  responses during acute SARS-CoV-2 infection. Nat. Immunol. 22, 1428–1439.
  10.1038/s41590-021-01028-7.
- 38. Cheemarla, N.R., Watkins, T.A., Mihaylova, V.T., Wang, B., Zhao, D., Wang, G., Landry,
  M.L., and Foxman, E.F. (2021). Dynamic innate immune response determines susceptibility
  to SARS-CoV-2 infection and early replication kinetics. J. Exp. Med. *218*, e20210583.
  10.1084/jem.20210583.
- 39. Hou, W., Kang, H.S., and Kim, B.S. (2009). Th17 cells enhance viral persistence and inhibit
  T cell cytotoxicity in a model of chronic virus infection. J. Exp. Med. 206, 313–328.
  10.1084/jem.20082030.
- 40. Medzhitov, R., Schneider, D.S., and Soares, M.P. (2012). Disease Tolerance as a Defense
  Strategy. Science *335*, 936–941. 10.1126/science.1214935.
- 41. Martins, R., Carlos, A.R., Braza, F., Thompson, J.A., Bastos-Amador, P., Ramos, S., and
  Soares, M.P. (2019). Disease Tolerance as an Inherent Component of Immunity. Annu. Rev.
  Immunol. *37*, 405–437. 10.1146/annurev-immunol-042718-041739.
- 42. Islam, H., Chamberlain, T.C., Mui, A.L., and Little, J.P. (2021). Elevated Interleukin-10
  Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired AntiInflammatory Action? Front. Immunol. *12*.
- 43. Lu, L., Zhang, H., Dauphars, D.J., and He, Y.-W. (2021). A Potential Role of Interleukin 10
  in COVID-19 Pathogenesis. Trends Immunol. *42*, 3–5. 10.1016/j.it.2020.10.012.
- 44. Moseman, E.A., Wu, T., Torre, J.C. de la, Schwartzberg, P.L., and McGavern, D.B. (2017).
  Type I interferon suppresses neutralizing antiviral B cell responses by modulating CD8+ T
  cell differentiation. J. Immunol. *198*, 122.1-122.1.

It is made available under a CC-BY 4.0 International license .

- 45. Bardel, E., Doucet-Ladeveze, R., Mathieu, C., Harandi, A.M., Dubois, B., and Kaiserlian, D.
  (2016). Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces
  mucosal antibody responses and protects against genital HSV-2 infection. NPJ Vaccines *1*,
  16010. 10.1038/npjvaccines.2016.10.
- 46. Garcia-Beltran, W.F., Lam, E.C., Astudillo, M.G., Yang, D., Miller, T.E., Feldman, J.,
  Hauser, B.M., Caradonna, T.M., Clayton, K.L., Nitido, A.D., et al. (2021). COVID-19neutralizing antibodies predict disease severity and survival. Cell *184*, 476-488.e11.
  10.1016/j.cell.2020.12.015.
- Krause, P.R., Fleming, T.R., Longini, I.M., Peto, R., Briand, S., Heymann, D.L., Beral, V.,
  Snape, M.D., Rees, H., Ropero, A.-M., et al. (2021). SARS-CoV-2 Variants and Vaccines.
  N. Engl. J. Med. *385*, 179–186. 10.1056/NEJMsr2105280.
- 48. Alvim, R.G.F., Lima, T.M., Rodrigues, D.A.S., Marsili, F.F., Bozza, V.B.T., Higa, L.M.,
- Monteiro, F.L., Abreu, D.P.B., Leitão, I.C., Carvalho, R.S., et al. (2022). From a
- recombinant key antigen to an accurate, affordable serological test: lessons learnt from
- COVID-19 for future pandemics. Biochem. Eng. J., 108537. 10.1016/j.bej.2022.108537.

875

876